Relmacabtagene autoleucel (CAR-T)
倍诺达 (Carteyva)
A CAR-T cell therapy developed in China (JW Therapeutics), one-time infusion of re-engineered T-cells.
At a glance
China price
¥1,290,000 per infusion
What this meansChecked against a primary or official source.
Source(s)
- 163.com/dy/article/JE0BDJK60552IJOG.html
Secondary source (media / community / commercial) - xueqiu.com/4097176039/338291915
Secondary source (media / community / commercial)
Last checked2026-09-08
Noteslist price
NRDL (national insurance)
Not in NRDL — self-pay; efficacy-linked refund program exists.
Regulatory status
NMPA approved (2021); not in NRDL
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
International comparison
No direct US equivalent product; comparable CAR-T class USD 400-500k
What this meansReported information that has not yet been independently confirmed.
SourceNo independent source on file.
NotesReported comparison, not independently verified.
What it treats
Relapsed/refractory large B-cell lymphoma; follicular lymphoma.
How it is accessed in China
- Certified tertiary hospitals
China-developed CAR-T.
Related treatments
Sources & verification
- 163.com/dy/article/JE0BDJK60552IJOG.html — Secondary source (media / community / commercial)
- xueqiu.com/4097176039/338291915 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Relmacabtagene autoleucel (CAR-T). Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.